CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
Live CME Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2012-07-17): Milk thistle extract doesn't ease hepatitis C

Clinical

Milk thistle extract doesn't ease hepatitis C

Last Updated: 2012-07-17 17:00:06 -0400 (Reuters Health)

NEW YORK (Reuters Health) - A popular but unproven alternative therapy for liver disease may not offer any relief for those with chronic hepatitis C infection, a new study suggests.

Research has suggested as many as one-third of people with hepatitis C have tried the milk thistle extract known as silymarin.

But in the new study, the extract was no better than a placebo at easing signs of the disease among people who hadn't responded to peginterferon and ribavirin.

"Taking (silymarin) would be unlikely to have any benefit for them," said Dr. Michael Fried, the lead researcher on the new study from the University of North Carolina at Chapel Hill.

"Focusing on keeping a healthy lifestyle to try to minimize liver damage - that's probably more important than taking these supplements," Dr. Fried told Reuters Health.

In his new study, sponsored by the National Institutes of Health, 154 people with chronic hepatitis C who hadn't gotten any better taking standard prescription drugs were randomly assigned to down one of two doses of silymarin or a placebo, three times a day for almost half a year.

Both doses of silymarin - 420 milligrams and 700 mg - were higher than the traditional amount in most supplements.

At the beginning and end of the study period, the researchers measured levels of serum alanine aminotransferase (ALT) in patients' blood.

And after 24 weeks of treatment, only six people - two in each silymarin group and two in the placebo group - saw their enzyme levels return to normal (45 U/L or less) or at least drop enough to suggest significant improvement, according to findings published July 17 in the Journal of the American Medical Association.

That finding "certainly does not provide any real rationale or reason for patients with chronic hepatitis C to use milk thistle or silymarin in hopes of having a beneficial effect," said Dr. Herbert Bonkovsky, head of research at the Liver-Biliary-Pancreatic Center at Carolinas HealthCare System in Charlotte, North Carolina.

Dr. Bonkovsky said it may be that doses of silymarin, an antioxidant, are just too low when the extract is taken orally. Preliminary research, he noted, suggests daily intravenous versions may be a better - though less convenient - option.

The supplements tested by Dr. Fried and his colleagues were donated by Rottapharm Madaus, which markets silymarin in Europe and Asia, and some of the researchers have received grants from that and other pharmaceutical companies.

The supplements were not tied to any side effects in the new study, and Dr. Bonkovsky said milk thistle seems to be safe. But he still cautioned that because dietary supplements "are not really regulated in any meaningful way," it's hard for patients to know exactly what they're buying.

Besides silymarin, another alternative for people with liver disease who also have high iron levels is iron-reduction therapy to prevent liver scarring, according to Dr. Bonkovsky, who wasn't involved in the new research.

Dr. Fried said the focus for people who don't respond to traditional liver drugs should be on improving their lifestyle.

"Avoiding things like alcohol and maintaining your ideal body weight will go a long way toward maintaining liver health in people with hepatitis C," Dr. Fried said.

In addition, he added, "It's important to stress that there are a lot of advances in hepatitis C (treatment) for people who previously didn't respond to interferon-based medication."

SOURCE: http://bit.ly/PN66Br

JAMA, 2012.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
Live CME Meetings
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Live CME Meetings
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.